Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

BACKGROUND: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy. METHODS: All patients with HR-positive metastatic breast cancer treated with siroli...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Breast
Egile Nagusiak: Yi, Zongbi, Liu, Binliang, Sun, Xiaoying, Rong, Guohua, Wang, Wenna, Li, Hui, Guan, Xiuwen, Li, Lixi, Zhai, Jingtong, Li, Chunxiao, Qian, Haili, Ma, Fei, Xu, Binghe
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375615/
https://ncbi.nlm.nih.gov/pubmed/32335491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.04.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak